KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Regeneron Pharmaceuticals' Cost of Revenue rose 7.13% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 12.74%. This contributed to the annual value of $1.1 billion for FY2024, which is 16.65% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cost of Revenue of $1.1 billion as of FY2024, which was up 16.65% from $932.1 million recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cost of Revenue peaked at $1.8 billion during FY2021, and registered a low of $628.0 million during FY2020.
  • Its 3-year average for Cost of Revenue is $939.8 million, with a median of $932.1 million in 2023.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Cost of Revenue spiked by 182.34% in 2021 and then slumped by 54.88% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cost of Revenue (Yearly) stood at $628.0 million in 2020, then spiked by 182.34% to $1.8 billion in 2021, then tumbled by 54.88% to $800.0 million in 2022, then rose by 16.51% to $932.1 million in 2023, then increased by 16.65% to $1.1 billion in 2024.